Suppr超能文献

微波消融治疗小乳头状甲状腺癌:临床疗效及甲状腺功能保留

Microwave ablation for small papillary thyroid carcinomas: clinical outcomes and thyroid function preservation.

作者信息

Zhao Lu, Peng Xiaolin, Xiong Jianning, Zhu Yanhui, Song Mu

出版信息

Endocr Connect. 2025 Feb 26;14(4). doi: 10.1530/EC-24-0628. Print 2025 Apr 1.

Abstract

PURPOSE

This study explores the impact of microwave ablation (MWA) on thyroid function in patients with small papillary thyroid carcinomas (SPTCs) using a specific energy/volume model to optimize treatment and evaluate clinical efficacy.

METHODS

A cohort of 70 patients with confirmed SPTCs underwent MWA tailored to individual nodule characteristics. Pre- and post-ablation assessments included ultrasound imaging for nodule size and thyroid function tests (thyroid-stimulating hormone, free thyroxine and free triiodothyronine levels) were conducted at baseline, 1, 3, 6 and 12 months post-treatment. The main results are the complete ablation rate of nodules and the stability of thyroid function after treatment. Secondary outcomes include the incidence of complications and other clinical parameters.

RESULTS

The complete ablation rate was achieved in 95% of the nodules, with most patients (90%) requiring a single ablation session. Nodule size reduced significantly from an average of 174.0 ± 259.1 to 3.2 ± 11.3 mm3, with a mean volume reduction rate of 98.47 (5.82%) at the 18-month follow-up. Stable thyroid function and minimal fluctuations in hormone levels were observed in 90% of patients, demonstrating the effectiveness of MWA in preserving thyroid function. Notably, lower energy/volume ratios were linked to a reduced risk of complications and preservation of thyroid function. Only 5% of patients reported minor complications, with no major adverse events.

CONCLUSIONS

The study's results validate the clinical utility of MWA in energy/volume setting as an effective, minimally invasive treatment for SPTCs.

摘要

目的

本研究采用特定的能量/体积模型,探讨微波消融(MWA)对微小乳头状甲状腺癌(SPTC)患者甲状腺功能的影响,以优化治疗并评估临床疗效。

方法

70例确诊为SPTC的患者队列接受了根据个体结节特征量身定制的MWA治疗。消融前后的评估包括超声成像测量结节大小,以及在基线、治疗后1、3、6和12个月进行甲状腺功能测试(促甲状腺激素、游离甲状腺素和游离三碘甲状腺原氨酸水平)。主要结果是结节的完全消融率和治疗后甲状腺功能的稳定性。次要结果包括并发症的发生率和其他临床参数。

结果

95%的结节实现了完全消融,大多数患者(90%)只需进行一次消融治疗。结节大小从平均174.0±259.1显著减小至3.2±11.3mm³,在18个月随访时平均体积缩小率为98.47(5.82%)。90%的患者甲状腺功能稳定,激素水平波动极小,表明MWA在保留甲状腺功能方面有效。值得注意的是,较低的能量/体积比与并发症风险降低和甲状腺功能保留有关。仅5%的患者报告有轻微并发症,无重大不良事件。

结论

该研究结果证实了MWA在能量/体积设置下作为SPTC的一种有效、微创治疗方法的临床实用性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验